Half of all people diagnosed die within three months. Only about 3% survive five years once the disease has spread to other organs.
A pill that can shrink and, in a small share of cases, leave pancreatic tumours undetectable is being hailed as the biggest treatment breakthrough for the cancer in decades.
The drug, daraxonrasib, was given to 61 patients recently diagnosed with advanced pancreatic cancer that had already spread to other parts of the body.
Tumours stopped growing in 90% of patients, and in almost all of those on the trial. Just over 60% had tumours that shrank or disappeared.
In about 8% of patients, one in 12, the cancer became undetectable on CT scans.
A year after treatment started, 76.6% of patients were alive. On chemotherapy alone, doctors usually see 40% to 45% survive a year.
Patients were followed for a year and a half on average. Some did not see the cancer return in that time.
Daraxonrasib is a KRAS inhibitor. It works by locking on to and shutting off mutations found in most pancreatic cancers.
The stakes are high. Pancreatic cancer has the lowest survival rate of all common cancers in the UK and a similarly poor prognosis worldwide.
Doctors said the pill cannot yet be considered a cure, and they do not know how long it can hold the disease back. They called the findings encouraging because it appears to offer patients more time, even without full remission.
One doctor said:"We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival.".
Longer studies will test whether any of the cancers can be put into remission. Further trials are also needed before the treatment can be assessed for use on the NHS.
Despite the advance, survival from pancreatic cancer remains very low.